Title of article
Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population: A Report From the e-SELECT (Multi-Center Post-Market Surveillance) Registry
Author/Authors
Urban، نويسنده , , Philip and Abizaid، نويسنده , , Alexandre and Banning، نويسنده , , Adrian and Bartorelli، نويسنده , , Antonio L. and Baux، نويسنده , , Ana Cebrian and D?av?k، نويسنده , , Vladim?r and Ellis، نويسنده , , Stephen and Gao، نويسنده , , Runlin and Holmes، نويسنده , , David and Jeong، نويسنده , , Myung Ho and Legrand، نويسنده , , Victor and Neumann، نويسنده , , Franz-Josef and Nyaker، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2011
Pages
10
From page
1445
To page
1454
Abstract
Objectives
m of this study was to ascertain the 1-year incidence of stent thrombosis (ST) and major bleeding (MB) in a large, unselected population treated with sirolimus-eluting stents (SES).
ound
thrombosis and MB are major potential complications of drug-eluting stent implantation. Their relative incidence and predisposing factors among large populations treated worldwide are unclear.
s
S were implanted in 15,147 patients who were entered in a multinational registry. We analyzed the incidence of: 1) definite and probable ST as defined by the Academic Research Consortium; and 2) MB, with the STEEPLE (Safety and efficacy of Enoxaparin in PCI) definition, together with their relation to dual antiplatelet therapy (DAPT) and to 1-year clinical outcomes.
s
an age of the sample was 62 ± 11 years, 30.4% were diabetic, 10% had a Charlson comorbidity index ≥3, and 44% presented with acute coronary syndrome or myocardial infarction. At 1 year, the reported compliance with DAPT as recommended by the European Society of Cardiology guidelines was 86.3%. Adverse event rates were: ST 1.0%, MB 1.0%, mortality 1.7%, myocardial infarction 1.9%, and target lesion revascularization 2.3%. Multivariate analysis identified 9 correlates of ST and 4 correlates of MB. Advanced age and a high Charlson index were associated with an increased risk of both ST and MB. After ST, the 7-day and 1-year all-cause mortality was 30% and 35%, respectively, versus 1.5% and 10% after MB. Only 2 of 13,749 patients (0.015%) experienced both MB and ST during the entire 1-year follow-up period.
sions
s worldwide population treated with ≥1 SES, the reported compliance with DAPT was good, and the incidence of ST and MB was low. Stent thrombosis and MB very rarely occurred in the same patient. (The e-SELECT Registry: a Multicenter Post-Market Surveillance; NCT00438919)
Keywords
Coronary stent , Sirolimus-eluting stent , Stent thrombosis , drug-eluting stent , bleeding complication , Antithrombotic therapy
Journal title
JACC (Journal of the American College of Cardiology)
Serial Year
2011
Journal title
JACC (Journal of the American College of Cardiology)
Record number
1751785
Link To Document